By using bone scintigraphy, tumor metastases in the bone can be identified in the X-ray image before they become visible.
Bone scintigraphy (also known as skeletal scintigraphy) is a special nuclear medicine examination method in which the accumulation of a previously administered radioactive drug in the bone is measured. The distribution pattern and stored amount of the active ingredient allow conclusions to be drawn about an increased bone metabolism, as it occurs in metastases (settlements) of prostate carcinomas, among other things.
In contrast to radiological examination procedures (CT/MRI), which make changes in the structure of the bone visible, scintigraphy primarily reveals unusual changes in bone metabolism. However, noticeable scintigraphic findings are not evidence of metastases. They can also occur with benign bone diseases or wear and tear of the joints (arthrosis).
Bone scintigraphy should be performed in prostate carcinoma patients to rule out tumor metastasis in the bones whenever larger prostate carcinomas (PSA > 20 ng/ml) or more aggressive tumor types (Gleasonscore > 7) are involved.